Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Aceruloplasminemia

Metabolic & Lysosomal

Aceruloplasminemia Clinical Trials and Treatments

Also called iron accumulation disease, ceruloplasmin deficiency, HEPB mutation

Aceruloplasminemia is a rare autosomal recessive disorder of iron metabolism caused by mutations in the CP gene (chromosome 3) encoding ceruloplasmin, a copper-carrying ferroxidase essential for iron metabolism and ferroxidase-mediated oxidation of iron from Fe2+ to Fe3+. Without ceruloplasmin, iron accumulates excessively in multiple organs particularly the brain, liver, pancreas, and retina, causing progressive neuronal and hepatic damage.

In plain words, aceruloplasminemia is a rare inherited condition where the body lacks a protein it needs to handle iron properly. Iron then slowly builds up in organs like the brain and liver, which can affect movement and thinking over time.

Get an email when new Aceruloplasminemia trials open or the FDA decides. Get alerts

Aceruloplasminemia

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 study with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Aceruloplasminemia yet.

Aceruloplasminemia has no FDA-approved medicines, 1 open or active clinical trial (1 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

More about Aceruloplasminemia

Patients develop progressive parkinsonism with dystonia, rigidity, tremor, and bradykinesia typically beginning in young adulthood (typically 20s-40s), mimicking Parkinson's disease but with atypical features and earlier onset. Cognitive decline and dementia progress, often accompanying motor symptoms. Retinal degeneration with macular abnormalities leads to progressive vision loss and visual field defects. Hepatic iron accumulation causes cirrhosis in some patients with elevated transaminases and progressive liver dysfunction.

Keep reading about Aceruloplasminemia

Pancreatic iron deposition leads to diabetes mellitus and pancreatic insufficiency. Additional manifestations include hypogonadism and cardiac dysfunction. Serum ceruloplasmin is markedly reduced or absent (<10mg/dL, normal ~30mg/dL). Serum iron and ferritin are paradoxically elevated despite cellular iron deficiency due to impaired iron efflux. MRI shows characteristic iron accumulation predominantly in basal ganglia (globus pallidus, putamen) and substantia nigra.

What are the symptoms of Aceruloplasminemia?

These are common symptoms of Aceruloplasminemia, and how strong they are varies from person to person.

  • Progressive parkinsonism and movement disorder
  • Cognitive decline and dementia
  • Retinal degeneration causing vision loss
  • Liver disease and cirrhosis
  • Diabetes mellitus from pancreatic iron accumulation
  • Hypogonadism and cardiac dysfunction

Who gets Aceruloplasminemia?

Manifests in young adulthood (typically 20s-40s, range 16-45 years) with progressive neurological symptoms. Affects males and females equally with no gender predominance. Autosomal recessive inheritance requires mutations in both CP gene copies; parents are obligate carriers (heterozygotes) typically asymptomatic. Homozygous or compound heterozygous mutations cause disease.

Significantly more common in certain populations (Japan, Italy, Portugal, South Korea) where specific founder mutations documented. Extremely rare in other populations; fewer than 100 cases reported worldwide. Geographic clustering and founder mutations documented. Earlier onset in some families suggests possible genetic modifiers. Increased frequency in populations with consanguinity.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

How to get help paying for Aceruloplasminemia treatment

Charity funds and drugmaker programs for Aceruloplasminemia, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Aceruloplasminemia

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Aceruloplasminemia resources

Reputable organizations and medical references for learning more about Aceruloplasminemia, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Aceruloplasminemia

Use this Aceruloplasminemia clinical trial finder to see the 1 study recruiting patients in the United States and worldwide, with eligibility criteria in plain English. It does not test a treatment; it follows patients over time. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

1 active trial worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenHasn't posted an update in over a yearNCT05522374

TIRCON International NBIA Registry

Sponsor: LMU Klinikum

TIRCON-reg aims to

* continue the provision of a global registry and natural history study for NBIA disorders

* harmonize and cover existing national and single site registries

* enable participation of countries and single sites that so far have no access to an NBIA registry

Ages not specified
Started Jun 2012Updated 1 year agoEst. Dec 2040 (~14y 1m)
Find Aceruloplasminemia trials near you, ranked by distance →
Active trial locations8 cities
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Aceruloplasminemia trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run an Aceruloplasminemia foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Aceruloplasminemia patient communities

Facebook groups, Reddit communities and YouTube channels where Aceruloplasminemia patients, caregivers and advocacy groups talk.

Questions people ask about Aceruloplasminemia